Gary J. Nabel

Gary J. Nabel

Auto-generated profile, based on publicly available information

Gary J. Nabel

Sanofi, Cambridge, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2010 in Science
Verified
Journal Article
Closed access
PDF file
XWXueling Wu
Xueling Wu
ZYZhi-Yong Yang
Zhi-Yong Yang
YLYuxing Li
Yuxing Li
CHCarl-Magnus Hogerkorp
Carl-Magnus Hogerkorp
WSWilliam R. Schief
William R. Schief
JMJohn Mascola
John Mascola
Designer Anti-HIV: Developing a protective HIV vaccine remains a top global health priority. One strategy to identify potential vaccine candidates is to isolate broadly neutralizing antibodies from infected individuals and then attempt to elicit the same antibody response through vaccination (see the Perspective by Burton and Weiss ). Wu et al. (p. 856 , published online 8 July) now report the identification of three broadly neutralizing antibodies, isolated from an HIV-1–infected individual, that exhibited great breadth and potency of neutralization and were specific for the co-receptor CD4-binding site of the glycoprotein 120 (gp120), part of the viral Env spike. Zhou et al. (p. 811 , published online 8 July) analyzed the crystal structure for one of these antibodies, VRC01, in complex with an HIV-1 gp120. VRC01 focuses its binding onto a conformationally invariant domain that is the site of initial CD4 attachment, which allows the antibody to overcome the glycan and conformational masking that diminishes the neutralization potency of most CD4-binding-site antibodies. The epitopes recognized by these antibodies suggest potential immunogens that can inform vaccine design.

22 May 2013 in Nature
Verified
Journal Article
Closed access
PDF file
MKMasaru Kanekiyo
Masaru Kanekiyo
CWChih-Jen Wei
Chih-Jen Wei
HYHadi M. Yassine
Hadi M. Yassine
PMPatrick M. McTamney
Patrick M. McTamney
JBJeffrey C. Boyington
Jeffrey C. Boyington
GNGary J. Nabel
Gary J. Nabel

1 April 2004 in Nature
Verified
Journal Article
Closed access
ZYZhi-Yong Yang
Zhi-Yong Yang
WKWing-Pui Kong
Wing-Pui Kong
YHYue Huang
Yue Huang
ARAnjeanette Roberts
Anjeanette Roberts
BMBrian R. Murphy
Brian R. Murphy
GNGary J. Nabel
Gary J. Nabel

28 January 2010 in Nature Medicine
Verified
Journal Article
Open access
PDF file
WAWataru Akahata
Wataru Akahata
ZYZhi-Yong Yang
Zhi-Yong Yang
HAHanne Andersen
Hanne Andersen
SSSiyang Sun
Siyang Sun
HHHeather A Holdaway
Heather A Holdaway
GNGary J Nabel
Gary J Nabel
Chikungunya virus (CHIKV) is an emerging infectious agent that can cause severe disease in humans and against which there is presently no vaccine. Akahata et al. now describe their development of a virus-like particle (VLP) vaccine that elicits neutralizing antibodies against CHIKV and can protect nonhuman primates from infection. Their VLP-based approach may facilitate development of a CHIKV vaccine for human use. Chikungunya virus (CHIKV) has infected millions of people in Africa, Europe and Asia1,2 since this alphavirus reemerged from Kenya in 2004. The severity of the disease and the spread of this epidemic virus present a serious public health threat in the absence of vaccines or antiviral therapies. Here, we describe a new vaccine that protects against CHIKV infection of nonhuman primates. We show that selective expression of viral structural proteins gives rise to virus-like particles (VLPs) in vitro that resemble replication-competent alphaviruses. Immunization with these VLPs elicited neutralizing antibodies against envelope proteins from alternative CHIKV strains. Monkeys immunized with VLPs produced high-titer neutralizing antibodies that protected against viremia after high-dose challenge. We transferred these antibodies into immunodeficient mice, where they protected against subsequent lethal CHIKV challenge, indicating a humoral mechanism of protection. Immunization with alphavirus VLP vaccines represents a strategy to contain the spread of CHIKV and related pathogenic viruses in humans.

1 June 2004 in Journal of Virology
Verified
Journal Article
Open access
PDF file
ZYZhi-Yong Yang
Zhi-Yong Yang
YHYue Huang
Yue Huang
LGLakshmanan Ganesh
Lakshmanan Ganesh
KLKwanyee Leung
Kwanyee Leung
WKWing-Pui Kong
Wing-Pui Kong
GNGary J. Nabel
Gary J. Nabel
The severe acute respiratory syndrome coronavirus (SARS-CoV) synthesizes several putative viral envelope proteins, including the spike (S), membrane (M), and small envelope (E) glycoproteins. Although these proteins likely are essential for viral replication, their specific roles in SARS-CoV entry have not been defined. In this report, we show that the SARS-CoV S glycoprotein mediates viral entry through pH-dependent endocytosis. Further, we define its cellular tropism and demonstrate that virus transmission occurs through cell-mediated transfer by dendritic cells. The S glycoprotein was used successfully to pseudotype replication-defective retroviral and lentiviral vectors that readily infected Vero cells as well as primary pulmonary and renal epithelial cells from human, nonhuman primate, and, to a lesser extent, feline species. The tropism of this reporter virus was similar to that of wild-type, replication-competent SARS-CoV, and binding of purified S to susceptible target cells was demonstrated by flow cytometry. Although myeloid dendritic cells were able to interact with S and to bind virus, these cells could not be infected by SARS-CoV. However, these cells were able to transfer the virus to susceptible target cells through a synapse-like structure. Both cell-mediated infection and direct infection were inhibited by anti-S antisera, indicating that strategies directed toward this gene product are likely to confer a therapeutic benefit for antiviral drugs or the development of a SARS vaccine.

1 August 2003 in Nature
Verified
Journal Article
Closed access
PDF file
NSNancy J. Sullivan
Nancy J. Sullivan
TGThomas W. Geisbert
Thomas W. Geisbert
JGJoan B. Geisbert
Joan B. Geisbert
LXLing Xu
Ling Xu
ZYZhi-Yong Yang
Zhi-Yong Yang
GNGary J. Nabel
Gary J. Nabel